Neoplasms

Digestive System Diseases

All Conditions

Colorectal Neoplasms

Intestinal Neoplasms

Gastrointestinal Neoplasms

Digestive System Neoplasms

Gastrointestinal Diseases

Colonic Diseases

Intestinal Diseases

Rectal Diseases

Antineoplastic Agents

All Drugs and Chemicals

Trametinib

Panitumumab

Antineoplastic Agents, Immunological

Protein Kinase Inhibitors

Enzyme Inhibitors

Trametinib: 2 mg QD, orally, continuously.

Panitumumab: 6 mg/kg, intravenously, Q2W

Philippe Bedard, M.D.

This is a phase 2 study (the second phase in testing a new drug or drug combination) to see how useful the combination of two drugs, panitumumab and trametinib, are in patients with advanced colorectal cancer with KRAS, NRAS, or BRAF wild type (genes that are not mutated).

Panitumumab is a drug that is approved by Health Canada for the treatment of advanced colorectal cancer with KRAS wild type. Panitumumab works by binding to and blocking the protein, epidermal growth factor receptor (EGFR) from working.

Trametinib is a drug that is approved by Health Canada for the treatment of melanoma with a mutation in the BRAF gene. Trametinib works by binding to and blocking mitogen-activated protein kinase kinase (MEK) 1 and MEK2 from working.

Previous studies have shown that the combination of panitumumab and trametinib may be more useful in KRAS, NRAS, or BRAF wild type colorectal cancer.

A Trial of Trametinib and Panitumumab in RAS/RAF Wild Type Advanced Colorectal Cancer

Molecular Basket Trial In Multiple Malignancies With Common Target Pathway Aberrancies

University Health Network, Toronto

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization	Link
A Trial of Trametinib and Panitumumab in RAS/RAF Wild Type Advanced Colorectal Cancer	NCT02399943	Colorectal Canc... KRAS Wildtype NRAS Wildtype BRAF Wildtype	Trametinib Panitumumab	18 Years -	University Health Network, Toronto
A Trial of Trametinib and Panitumumab in RAS/RAF Wild Type Advanced Colorectal Cancer	NCT02399943	Colorectal Canc... KRAS Wildtype NRAS Wildtype BRAF Wildtype	Trametinib Panitumumab	18 Years -	University Health Network, Toronto

Spots Global Cancer Trial Database for nras wildtype